SCHEMBL15207732

SCHEMBL15207732

CN(C)c1ccc(-c2nccn3nc(Nc4ccc(CO)cc4)nc23)cn1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
JAK3 P52333 11/20 0.38
LCK P06239 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
JAK2 O60674 13/20 0.37
PTK2 Q05397 9/20 0.37
PDE4B Q07343 2/20 0.35
PDE4D Q08499 2/20 0.35
MAPT P10636 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
JAK1 P23458 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20136 0.87 SYK (0.39) SYKEIF2AK4JAK3PSEN1PSEN2
SCHEMBL19667 0.86 SYK (0.39) SYKEIF2AK4JAK3JAK2PTK2
SCHEMBL15206837 0.85 SYK (0.42) SYKEIF2AK4JAK3PSEN1PSEN2
SCHEMBL15208007 0.85 JAK2 (0.48) JAK3JAK2PTK2MAPT
SCHEMBL21741 0.85 SYK (0.39) SYKEIF2AK4JAK3JAK2PTK2
SCHEMBL20913 0.84 JAK2 (0.51) SYKEIF2AK4JAK3PSEN1PSEN2
SCHEMBL15207717 0.83 JAK2 (0.48) SYKEIF2AK4JAK3JAK2PTK2
SCHEMBL21220 0.82 CHEK1 (0.38) SYKEIF2AK4JAK3JAK2PTK2
SCHEMBL20559 0.82 SYK (0.38) SYKEIF2AK4JAK3JAK2PTK2
SCHEMBL15207567 0.82 KIT (0.40) JAK3JAK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 SYK 1/4885EIF2AK4 1898/4885JAK3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.